Hydrogen IV Therapy Safe for Stroke Patients in Clinical Trial

Safety of intravenous administration of hydrogen-enriched fluid in patients with acute cerebral ischemia: Initial clinical studies

Research hubs: Brain & Nervous System · Cardiovascular System

Evidence type
Uncontrolled trial (single-arm or pilot) · Human study
Authors
Kimihiro Nagatani, Hiroshi Nawashiro, Satoru Takeuchi, Satoshi Tomura, Naoki Otani, Hideo Osada, Kojiro Wada, Hiroshi Katoh, Nobusuke Tsuzuki, Kentaro Mori
Journal
Medical Gas Research
Year
2013
DOI
10.1186/2045-9912-3-13
Study Type
Human
Outcome
Positive
Peer Reviewed
Yes
Country
Japan
Health Condition
Acute Ischemic Stroke
Body System
Nervous System

TL;DR

A pilot study suggests that intravenous hydrogen therapy is safe for stroke patients, even when used with a common stroke medication.

Key Finding

Intravenous hydrogen-enriched fluid was well-tolerated in 38 acute stroke patients, with only minor complications in 5.3% and no serious adverse events, even when combined with clot-busting medication.

Summary

This pilot study tested whether giving patients with acute ischemic stroke (a type of stroke caused by a blood clot) an intravenous solution enriched with hydrogen gas was safe. Thirty-eight stroke patients received the hydrogen-enriched fluid along with standard treatments. Only 2 patients experienced minor side effects (diarrhea and heart failure), and no serious complications or concerning lab or heart changes were observed. Patients' stroke severity scores improved over the 90-day follow-up period.

Practical Takeaway

This small, early-stage human study suggests that hydrogen therapy may be safe as an add-on treatment for acute stroke, but it was not designed to prove whether hydrogen actually helps patients recover better. Much larger, controlled studies would be needed to determine whether hydrogen provides real therapeutic benefit beyond standard stroke care.

Abstract (excerpt)

Most of the results regarding hydrogen (H2) therapy for acute cerebral ischemia are derived from in vitro studies and animal experiments, with only a few obtained from human trials with a limited number of subjects. Thus, there is a paucity of information regarding both the beneficial therapeutic…

Read the full abstract via DOI